Zenotech Laboratories Limited (Zenotech) is an India-based company that is principally engaged in the manufacture and trading of pharmaceuticals. The Company has launched 15 generic chemical oncology and anesthesiology products in India. Zenotech has three biological products: recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF), recombinant human granulocyte colony stimulating factor (G-CSF) and interlukin-2 (IL-2). All the three are used in the cancer therapy area. The Company’s wholly owned subsidiaries include Zenotech Farmaceutica Do Brasil Limitada, Zenotech Laboratories Nigeria Limited and Zenotech Inc. On May 31, 2007, the Company incorporated a wholly owned subsidiary Hemarus Biologicals Limited.
Zenotech Laboratories Limited
BOM:532039 ISIN:INE486F01012
News
Yesterday the Australian stock market ended the day lower, led by financial stocks, on renewed worries about banking industry worldwide. The benchmark S&P/ASX200 index was down 1%, or 33.8 points, at 3442.8, while the broader All Ordinaries index was lower by 0.9%, or 30.2 points, at 3394.8. Regulator ASIC's move to extend a ban on covered short-selling of financial securities would give a positive lead to the banking industry.
###
39,347 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 7) (Last 30 Days: 25) (Since Published: 7046)